CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New combo therapy before surgery shows promise for esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Virus therapy joins chemo-radiation in fight against esophageal cancer
Disease control OngoingThis early-phase trial is testing whether adding a cancer-killing virus (OBP-301) to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The study involves 16 participants and focuses on side effects …
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
Immunotherapy combo shows promise for genetic stomach cancer subtype
Disease control OngoingThis study looks at whether an immunotherapy drug (atezolizumab) alone or combined with chemotherapy can help control a certain type of stomach or gastroesophageal junction cancer that has a genetic feature called MSI-H/dMMR. About 240 adults with localized or locoregional cancer…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New combo therapy before surgery shows promise for esophageal cancer
Disease control OngoingThis study tests whether giving a mix of chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) before surgery can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The trial includes about 3 adul…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Hot chemo wash during surgery may stop stomach Cancer's return
Prevention ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the belly lining. It is for patients at high risk of recurrence. The approach aims to kill any stray cancer cells…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 10, 2026 13:28 UTC